3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
NIH
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Lung Neoplasms
3
Carcinoma, Non-Small-Cell Lung
3
Breast Neoplasms
3
Stomach Neoplasms
2
Rectal Neoplasms
2
Pancreatic Neoplasms
2
Barrett Esophagus
2
Triple Negative Breast Neoplasms
1
Thyroid Nodule
1
Smoking Cessation
1
Small Cell Lung Carcinoma
1
Recurrence
1
Prostatic Neoplasms
1
Neoplastic Cells, Circulating
1
Neoplasms
1
Neoplasm Metastasis
1
Multiple Pulmonary Nodules
1
Lung Diseases
1
Hypoxia
1
Head and Neck Neoplasms
1
Gastrointestinal Neoplasms
1
Fallopian Tube Neoplasms
1
Esophageal Neoplasms
1
Colorectal Neoplasms
1
Colonic Neoplasms
1
Cardiotoxicity
1
Carcinoma, Ovarian Epithelial
1
Carcinoma
1
Breast Neoplasm Female
1
Adenocarcinoma of Lung
1
Interventions
Etoposide
154
Carboplatin
142
Cisplatin
104
Topotecan
74
durvalumab
48
atezolizumab
46
Irinotecan
44
pembrolizumab
39
Paclitaxel
34
Nivolumab
33
Radiotherapy
29
anlotinib
23
PM 01183
22
Gemcitabine
21
Drug Therapy
20
apatinib
19
Ipilimumab
18
Docetaxel
17
Temozolomide
16
Platinum
16
Radiosurgery
15
Pemetrexed
14
toripalimab
13
tislelizumab
13
olaparib
13
Bevacizumab
13
amrubicin
11
Magnetic Resonance Spectroscopy
11
Cyclophosphamide
11
rovalpituzumab tesirine
10
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Small Cell Lung Carcinoma
×
Diagnostic Imaging
×
Clear all
NCT00047385
2014-05-20
NLST
National Cancer Institute (NCI)
Phase 3
Completed
53,454 enrolled
15 charts